Home > DocuBase > Article

« All DocuBase Articles

 

Follow DocuTicker on Twitter Bookmark and Share   Feed

Tuesday, 22nd July 2014

On Trial: Agricultural Biotechnology in Africa

Source: Chatham House

From Summary:

Increasing agricultural productivity and adapting farming to climate change are central to Africa’s development prospects. There are important opportunities to enhance yields and increase resilience through the adoption of improved crop varieties. In some cases, biotechnology, and in particular genetic modification (GM), offers advantages over conventional plant-breeding approaches. Accordingly there are various projects under way to develop new GM varieties for African farmers, ranging from drought-resistant maize to varieties of cassava, banana, sorghum, cowpea and sweet potato with resistance to pests and disease.

In addition to government funds, these projects have also attracted the support of influential donor agencies and philanthropic foundations. However, despite the expenditure of considerable resources, the potential of GM in Africa is not being realized. So far no GM trait developed for African farmers has been put to use.

Multiple barriers inhibit the development and adoption of pro-poor GM varieties in Africa. On the demand side, farmers may be reluctant to adopt GM varieties owing to a lack of export opportunities and distrust of the technology among local consumers. Farmers may also be concerned about exploitation by transnational seed companies (despite the fact that development of new GM technologies in Africa is dominated by the public sector). On the supply side, donor funding struggles to match the long timescales of research and development, while incentives among research scientists may be poorly aligned with farmer outcomes. Non-existent, poorly functioning or overly punitive regulatory regimes discourage investment.

The most important barriers – such as regulatory constraints, consumer distrust and weak farmer demand – must be understood in the context of wider social and political dynamics surrounding GM, typified by misinformation, polarized public discourse, and dysfunctional and opportunistic politics. The result is most GM projects becoming ‘stuck’ at the field trial stage without ever progressing to release.

+ Direct link to Report (PDF; 304 KB)


Category:

Source:

Views: 843


Having begun his career in academic libraries, Adrian Janes has subsequently worked extensively in public libraries, chiefly in enquiry work as an Information Services librarian. In this role he has had particular responsibility for information from both the UK Government and the European Union. He wrote a detailed report on sources for the latter which was published by FreePint in 2007, and has contributed articles to FreePint and ResourceShelf. He is involved in training in information literacy and the use of online reference resources.

A Contributing Editor to DocuTicker, he also write reviews for Pennyblackmusic.

Adrian can be reached at adrian.janes@freepint.com

More articles by Adrian Janes »



Please note: DocuTicker's editors collect citations for full-text PDF reports freely available on the web but we do not archive these reports. When you click a link to find and/or download the report, you are leaving the DocuTicker site. DocuTicker makes no representations regarding the ongoing availability of any report or any external resource. Links were accurate as of the date of posting.

« All DocuBase Articles

 

FreePint

FreePint supports the value of information in the enterprise. Read more »


FeedLatest FreePint Content:


  • Click to view the article Product Review of NewsEdge.com (Introduction; Contact Details)
    Friday, 17th October 2014

    Chris Porter reviews NewsEdge.com, a news management and delivery tool for business professionals that supports both current awareness and archive research. In the first part of his review he introduces the product and company, Acquire Media, and looks at typical users.

  • Click to view the article Q&A with Adis Custom Intelligence Service - Bespoke Pharma Research & Analysis
    Thursday, 16th October 2014

    The Adis Custom Intelligence Service consists of a flexible portfolio of solutions designed to answer some of the key questions facing the pharmaceutical industry and offers a variety of reports to provide more in-depth analysis in this area. In addition to serving the pharmaceutical industry, Adis Custom Intelligence helps non-pharmaceutical organisations who need to draw on specific industry research on a periodic basis, such as the financial and legal markets who may use it for due diligence and M&A purposes. Adis was bought by Springer in 2011. Sophie Alexander recently interviewed William Stow and Donald Schumacher to find out more about the product.

  • Click to view the article Product Review of the InfoDesk Suite (Technology - InfoWatch, InfoAlert, InfoMonitor)
    Thursday, 16th October 2014

    In the fourth part of her review of the InfoDesk suite, Constance Ard looks at how InfoWatch and InfoAlert deliver relevant content to users when, where and how they need it. She also examines the technology underpinning InfoMonitor, which provides daily competitive intelligence and custom reports.

  • ... more ...

All FreePint Content »
FreePint Topics »


A FreePint Subscription delivers articles and reports that support your organisation's information practice, content and strategy.

Find out more and order a FreePint Subscription by visiting the
completing our online form: Subscription Order page.


FreePint Testimonials

"First of all, let me thank you for your time in reviewing PharmaCircle. We certainly appreciate your effort, comments and professionalism. We ..."

Read more testimonials and supply yours »







 

 
 
 

Subscribe

Receive the DocuTicker Newsletter each week.

Find out more »

Article Categories

All Article Categories »

Sources

All DocuBase Sources »

Source Categories

All Source Categories »

Archive

All Archives »